T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

NCT00986557 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

78

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease
Nonneoplastic Condition

Interventions

BIOLOGICAL: adoptive immunotherapy
BIOLOGICAL: alemtuzumab
BIOLOGICAL: in vitro-treated peripheral blood lymphocyte therapy
DRUG: foscarnet sodium
DRUG: ganciclovir
GENETIC: polymerase chain reaction
PROCEDURE: allogeneic hematopoietic stem cell transplantation
PROCEDURE: infection prophylaxis and management
PROCEDURE: peripheral blood stem cell transplantation
PROCEDURE: standard follow-up care
RADIATION: radiation therapy

Sponsor

University Hospital Birmingham